Natalizumab
Title: Natalizumab
CAS Registry Number: 189261-10-7
CAS Name: Anti-(human integrin a4) immunoglobulin G4 (human-mouse monoclonal AN100226 g4-chain) disulfide with human-mouse monoclonal AN100226 light chain, dimer
Trademarks: Antegren (Elan); Tysabri (Elan)
Literature References: Recombinant humanized IgG4 monoclonal antibody directed against the leukocyte adhesion molecule VLA-4, also known as a4b1 integrin. a4-Integrin inhibitor designed to block lymphocyte activation, migration and adhesion to endothelial cells. Prepn: M. M. Bendig et al., WO 9519790; eidem, US 5840299 (1995, 1998 both to Athena Neurosciences); O. J. P. L├ęger et al., Hum. Antibod. 8, 3 (1997). Clinical pharmacokinetics: W. A. Sheremata et al., Neurology 52, 1072 (1999). Clinical trial in multiple sclerosis: D. H. Miller et al., N. Engl. J. Med. 348, 15 (2003); in Crohn's disease: W. J. Sandborn et al., ibid. 353, 1912 (2005). Review of pharmacology and therapeutic potential: M. Elices, Curr. Opin. Anti-Inflam. Immunomod. Invest. Drugs 2, 228-235 (2000); K. A. Keeley et al., Ann. Pharmacother. 39, 1833-1843 (2005).
Therap-Cat: Anti-inflammatory.
Keywords: Anti-inflammatory (Biological Response Modifier); Anti-inflammatory (Gastrointestinal).

Others monographs:
Leukotrienes3'-Methyl-1,2-cyclopentenophenanthreneSodium CyanateOblimersen Sodium
LycodinePyrantelLymecyclineAmmonium Uranium Fluoride
Vinbarbital SodiumPerfluorohexaneAngiotensinClofenamide
GentianCumic AlcoholPseudobaptigeninTaribavirin
©2016 DrugLead US FDA&EMEA